drug delivery science

Anziva Pharmaceuticals Inc. is a formulation-driven drug development company focused on improving how known therapeutic agents are delivered, combining pharmaceutical formulation science, product design, and regulatory strategy. It is initially focused on non-opioid pain products, with its lead program J'Neura™, a flexible, waterproof, non-opioid transdermal patch designed specifically for the knee. The company is led by founder and CEO Dr. Simerdeep Singh Gupta.

Read more

pharmaceutical formulation scienceproduct designreformulation of known moleculesregulatory strategytransdermal and topical delivery systems

Developing the Next Generation of RNA Medicines Axelyf is advancing RNA medicines for oncology and autoimmune diseases — powered by AXL, a next-generation lipid nanoparticle platform validated for precise, potent delivery. Explore our Platform View Programs An Asset Development Company Built on Cutting Edge Delivery Science Axelyf is developing RNA therapeutics that address diseases where conventional approaches have fallen short. Our focus is on building and advancing proprietary drug candidates — starting with AX-004, our lead in vivo CAR-T program targeting solid tumors, and AX-003, targeting autoimmune hepatitis. Both programs are enabled by the AXL platform: a next-generation lipid nanoparticle delivery system validated in non-human primates and optimized with the help of ANNA™, our proprietary AI model for lipid design. Meet the Team Latest News

Read more

AI-driven lipid designlipid chemistrylipid nanoparticle deliveryRNA biologyRNA therapeutics development